Activation of TLR3, TLR4, and TLR9 has been reported to reinforce the antitumor response to anti-PD-1/PD-L1 and exhibit immune checkpoint delayed resistance in glioma cells or animal models [187, 188, 190]. Here, TLR3 is linked to central nervous system cancer.